

Scientific Program

Ananta	Addala	USA	Solutions for equity: A call to action
Peter	Adolfsson	Sweden	Current use of connected pens
Stephanie	Amiel	UK	CGM detection of hypoglycemia in diabetes management
Lia	Bally	Switzerland	Virtual clinic for insulin therapy in type 2 diabetes
Katharine	Barnard-Kelly	UK	Consensus statement summary, navigating the maze of PROs
Tadej	Battelino	Slovenia	· CGM derived data on weekly insulins
			· CGM derived criteria for stage 2 type 1 diabetes
Richard	Bergenstal	USA	We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia
Mithun	Bhartia	India	Diabetes and sex life – the role of technology to improve quality of life
Bruce	Bode	USA	Management of glucose in the hospital with AID systems
Stefan	Bornstein	Germany	Islet Transplantation 2024
Emanuele	Bosi	Italy	Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool?
Charlotte	Boughton	UK	Cumulated experience with CamAPS in type 2 diabetes
Nataša	Bratina	Slovenia	Data on diabetes treatment in children below the age of six
Raffaella	Buzzetti	Italy	Antibody positivity in adult population
Anders	Carlson	USA	· The use of CGM in prediabetes and obesity
			· Use of AID in patients with type 2 diabetes
Eda	Cengiz	USA	Update on diabetes Female Technology (femtech)
Antonio	Ceriello	Italy	Weight and glycemic variability: Bad companions for CVD development in diabetes
Manoj	Chawla	India	Optimizing real time CGM in self pay markets
Patrik	Choudhary	UK	Implication of HypoMETRICS for reporting hypoglycemia in clinical trials
Mark	Clements	USA	Just in time adaptive interventions: The new technology to “hack” diabetes self-management behavior
Xavier	Cos	Spain	Use of CGM by the primary care providers
Amy	Criego	USA	CGM Success: Device start and ongoing data management to improve patient care
Tali	Cukierman-Yaffe	Israel	· How to measure and monitor sarcopenia and frailty
			· Diagnosis & monitoring of brain health in people with diabetes
Thomas	Danne	Germany	Worldwide progress achieving treatment targets in children with type 1 diabetes
Christophe	De Block	Belgium	Ketone continuous measurement – Is it needed?
Bastiaan	de Galan	The Netherlands	Impaired awareness of hypoglycemia
Sergio	di Molfetta	Italy	CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated
Klemen	Dovc	Slovenia	Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability
Celeste	Durnwold	USA	Can CGM replace the oral glucose tolerance test for diagnosis of Gestational diabetes?

Steven	Edelman	USA	· Top 10 tips to help people with diabetes (PwD) stay in range
			· With Jeremy Pettus – Rapid fire interpretations of CGM downloads
Laya	Ekhlaspour	USA	Beyond carbohydrate counting: Optimizing mealtime insulin dosing
Tara	Ettestad	USA	CGM guided or personalized nutrition
Chiara	Fabris	USA	· What do women want (and need)? Results from the large-scale IMAGINE survey
			· Simulation-enhanced closed-loop adaptation of long-acting insulin dosing in T2D
Leon	Farhy	USA	Diagnostic CGM
Andrea	Facchinetto	Italy	Digital twin technologies for treating diabetes
Deidre	Fitzgerald-Huges	Ireland	Shining a light on diabetic foot infections, development of novel photodynamic materials
Gregory	Forlenza	USA	Real-world data on hybrid closed-loop (HCL) in type 2 diabetes
Guido	Freckmann	Germany	International standard for evaluation of CGM systems: Approach of the IFCC
Juan	Frias	USA	Update on weekly insulin Efsitora
Satish	Garg	USA	Management options for treating obesity in type 1 diabetes patients
Michal	Gillon-Keren	Israel	Facilitate carb counting for people with diabetes
Francesco	Giorgino	Italy	Addressing glucose patterns in type 2 diabetes: Opportunities and challenges
Fernando	Gómez- Peralta	Spain	Connected insulin pens and caps: An expert's recommendation from the area of diabetes of the Spanish Endocrinology and Nutrition Society (SEEN)
Amit	Gupta	India	Challenges and opportunities in digital diabetes care in India
Michael	Haller	USA	Cost effectiveness of immune therapies in preserving beta cell function – Real world applications
Simon	Heller	UK	Should the classification of hypoglycemia be updated?
Irl	Hirsch	USA	What has the GMI taught us about A1C?
Roman	Hovorka	UK	Fully closed-loop in type 1 and type 2 diabetes
Daria	Igudesman	USA	Diet, microbiome, obesity and type 1 diabetes
Peter	Jacobs	USA	Unannounced meal detection algorithms: Can we eliminate manual meal boluses?
Laura	Jacobsen	USA	Immune therapy – Predicting responders/non-responders
Andrej	Janež	Slovenia	Incretins and taste
Johan	Jendle	Sweden	Interoperability of diabetes technology – Regulatory hurdle
Morten H	Jensen	Denmark	Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project
Shashank	Joshi	India	Artificial intelligence in diabetes care
Partha	Kar	UK	Widening clinical use of diabetes tech in the UK
Neal	Kaufman	USA	The importance and impact of family caregivers on a variety of outcomes for people with diabetes
Jothydev	Kesavadev	India	25 years of telemedicine Vs conventional care in diabetes: assessing vascular complications and quality of life
Kamlesh	Khunti	UK	Early intervention for type 2 diabetes in primary care
David	Klonoff	USA	Interoperability of diabetes technology – Academic view

Anna	Korsgaard Berg	Denmark	Skin problems caused by diabetes devices
Jernej	Kovac	Slovenia	Genetic background of obesity
Boris	Kovatchev	USA	Neural-Net artificial pancreas
Lori	Laffel	USA	Interventions to reduce health disparities in diabetes device use
Nebojsa	Lalic	Serbia	Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease
John	Leth	Denmark	The potential of open-source software in diabetes research
Alon	Liberman	Israel	Real world data from type 1 diabetes clinics
David	Maahs	USA	Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study
Julia	Mader	Austria	Lipohypertrophy and its effect on glucose control/insulin uptake/causes/detection/training and awareness of HCP and PwD
Roberto	Mallone	France	Benign autoimmunity & progression to type 1 diabetes
Marco	Marigliano	Italy	Relationships between insulin delivery system, CGM satisfaction and glucometrics
Brynn	Marks	USA	Insulin delivery is automated, but the education is not: Mothering diabetes technology users
Thomas	Martens	USA	CGM guided insulin management
Chantal	Mathieu	Belgium	CGM derived data on weekly insulins
Barbara	McGowan	UK	Medical therapies for treatment of obesity
Laurel	Messer	USA	Technology pearls for professionals
Nicola	Minuto	Italy	Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough
V	Mohan	India	Innovating to use existing technologies under resourced settings
Antoinette	Moran	USA	Impact of CGM in East Africa, research and translation
Helen	Murphy	UK	Should everyone with type 1 diabetes be offered closed-loop during pregnancy?
Mary	Murphy	UK	What inclusion of quality PRO assessment in clinical trials means to people with diabetes
Hamidah	Nabakka	Uganda	Diabetes advocate perspective on diabetes technology in low-income countries
Max	Nieuwdorp	The Netherlands	A balanced view on microbiome in obesity
Revital	Nimri	Israel	Maximizing glycemic control with automated insulin delivery in young children
Kirsten	Nørgaard	Denmark	· Low-dose glucagon to prevent hypoglycemia during exercise
			· Effects of GLP1 in type 1 diabetes
Alexander	Olbrechts	Belgium	Interoperability of diabetes technology – A company's view
Rakesh	Parikh	India	Artificial Intelligence in the management of diabetes
Anne	Peters	USA	Pod use for closed-loop in T2D
Jeremy	Pettus	USA	· With Steven Edelman – Rapid fire interpretations of CGM downloads
			· Insulin resistance in type 1 diabetes: An underappreciated problem
Heiko	Peuscher	Germany	A survey on existing open-source projects in diabetes simulation
Moshe	Phillip	Israel	From dream to reality – The Automated Insulin Delivery (AID) system

Ivana	Rabbone	Italy	Technology in the changing management of diabetes in children
Dario	Rahelić	Croatia	Use of CGM in nutrition management in type 2 diabetes
Yves	Reznik	France	Closed-loop as home care for type 2 diabetes: The Close study
Michael	Rickels	USA	Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes
Camillo	Ricordi	USA	From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions
Michael	Riddell	Canada	<ul style="list-style-type: none"> · CGM guided exercise · Lessons learned from the ongoing type 1 diabetes exercise research Initiative
Samantha	Roberts	UK	Bringing science into lives: a NICE perspective
Teresa	Rodriguez-Calvo	Germany	Role of viruses in pathogenesis of type 1 diabetes
Leocadio	Rodríguez Mañas	Spain	Current treatment options for sarcopenia in the context of frail older people with diabetes
Julio	Rosenstock	USA	Update on weekly insulin Icodec: The way of the future
Banshi	Saboo	India	Welcome and introduction to Dtech symposium
Andrea	Scaramuzza	Italy	Real-world data in very young AHCL users – Comparison among different systems
Desmond	Schatz	USA	Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors
Oliver	Schnell	Germany	What PROs mean in routine clinical care
Eleanor	Scott	UK	CGM glucose trajectories associated with large and small for gestational age birthweight
Elisabeth	Selvin	USA	<ul style="list-style-type: none"> · Diabetes and cognitive decline and dementia · Should A1C still be a diagnostic criterion for diabetes in 2024?
Viral	Shah	USA	GLP-1RA and SGLT in type 1 diabetes
Jennifer	Sherr	USA	Teplizumab therapy in the real world
Gregg	Simonson	USA	CGM (GMI/TIR) as diabetes quality metrics
Alan	Sinclair	UK	Sarcopenia in people living with diabetes
Jay	Skyler	USA	Stem cell approaches to type 1 diabetes
Darja	Šmigoc Schweiger	Slovenia	Guided management of diabetes in female
Tim	Street	UK	Interoperability of diabetes technology – Patient's view
Stuart	Weinzimer	USA	Strategies to facilitate technology use in disadvantaged youth with diabetes
Emma	Wilmot	UK	Technology-supported behavior intervention in type 2 diabetes (STAND)
Jane	Yardley	Canada	Challenges of exercise in women with type 1 diabetes
Yariv	Yogev	Israel	Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation?
Dessi	Zaharieva	USA	Translation of exercise guidelines into practical applications for type 1 diabetes

ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to share knowledge and develop collaborations.

Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.

You are invited to explore the Scientific Program!

[Interactive Program](#)[*Day by Day Schedule](#)[*Program Timetable](#)[*Program at a Glance](#)[*Interactive Program](#)[*Program Timetable](#)

*Correct as of 17 February 2025

ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to share knowledge and develop collaborations.

Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.

List of Confirmed Titles and Speakers

Anastasia	Albanese-O'Neill	USA	General population screening – Successes and pitfalls
Grazia	Aleppo	USA	Automated multi-hormone delivery approach to manage postprandial glycemic excursion
Kamil	Armacky	UK	<i>Together with Jazz Sethi: The benefits / disadvantages of social media in context of technology: The Diabfluencers</i>

Lia	Bally	Switzerland	· The role of estradiol in energy and glucose-insulin homeostasis
			· Perioperative closed-loop use during major surgery
Katharine	Barnard-Kelly	UK	· Spotlight-AQ – Harnessing AI to deliver the first step in the precision medicine pathway
			· Human behaviors that lead to optimal uptake / reception of automation
Tadej	Battelino	Slovenia	Consensus on the use of CGM in individuals with type 2 diabetes
Roy	Beck	USA	Cost benefits of CGM use in type 2 diabetes
Riccardo	Bellazzi	Italy	Machine learning methods predicting diabetes complications
Natalie	Bellini	USA	Sex differences in diabetes management in the primary care setting
Katrien	Benhalima	Belgium	Use of the Medtronic 780G hybrid closed-loop system in type 1 diabetes pregnancy
Richard	Bergenstal	USA	Real world data on CGM in type 2 diabetes – Glucose control improvement
Cari	Berget	USA	Simplifying devices: Practical tips for the clinician working with AID
Barbara Murn	Berkoperc	Slovenia	Periodic re-education for automated insulin delivery (AID)
Torben	Biester	Germany	2024 ISPAD Guidelines chapter on insulin delivery: Automation now for a better future
Bruce	Bode	USA	Managing glucose in the hospital with CGM and AID
Stefan	Bornstein	Germany	New strategies for curative therapies for diabetes
Emanuele	Bosi	Italy	Screening of type 1 diabetes and celiac disease of the general pediatric population in Italy: Progress and preliminary results
Charlotte	Boughton	UK	Closed-loop from diagnosis – What have we learnt from longest-ever closed-loop study?
Nick	Cahm	UK	The power of the patient voice: The Libre saga
Giacomo	Cappon	Italy	Creating digital twins: Model-driven and AI methods – An introduction
Anders	Carlson	USA	· Time in tight glycemic range: Overview of the physiological data
			· View, Counterpoint: Time in tight range should be the primary treatment goals and outcome measure in diabetes – View
Eda	Cengiz	USA	Leveraging technology to address gender differences in diabetes
Manoj	Chawla	India	Real-world data of CGM on GLP-1 usage
Pratik	Choudhary	UK	· Hypoglycemia and driving: Staying safe
			· The individual impact of hypoglycemia on daily living: Lessons for personalization
Mark	Clements	USA	Remote patient health in pediatric diabetes care – Where are we today?
Rosa	Corcoy	Spain	Real world experience of hybrid closed-loop use during type 1 diabetes pregnancy: A Spanish perspective
Tali	Cukierman-Yaffe	Israel	Assessment of cognitive & physical health agility in the busy diabetes clinic – The why & the how

Colin	Dayan	UK	DEBATE: Adaptive trials in the Post-Teplizumab era: To placebo or not to placebo? Yes, we should continue with placebo
Christophe	De Block	Belgium	90-minute aerobic exercise tests in people with type 1 diabetes using the 780G AID system. Examining timing of temporary target: The ACT-ONE study
Hans	DeVries	The Netherlands	Fully closed-loop – Bihormonal approaches
Klemen	Dovc	Slovenia	Planned versus spontaneous exercise in type 1 diabetes
Steven	Edelman	USA	DEBATE: Is there a real unmet need for continuous ketone monitoring? – CON
Dominic	Ehrmann	Germany	Objectively measured vs. subjective perceptions of glucose control: What is more important?
Laya	Ekhlaspour	USA	· Meal compositions and postprandial glycemic management in fully closed-loop systems
			· NAP @ Home – First outpatient studies of Neural-net artificial pancreas
Anas	El Fathi	USA	· Digital twins, replay simulation, and decision support
			· AI bolus calculator for people on multiple daily injections (MDI)
Juan	Espinoza	USA	Evidence and ideas from decision support systems on the user experience of automation
Chiara	Fabris	USA	· Glycemic excursion minimization (GEM): A lifestyle intervention for the management of type 2 diabetes
			· Impact of sex on the control of type 2 diabetes
Rodolfo	Galindo	USA	Future of novel basal insulins
Satish	Garg	USA	· CGM use and effect on hospitalization and ER visits in type 2 diabetes
			· Newer GLP analogs for treatment of obesity in type 1 diabetes
Samita	Garg	USA	Prevalence and rationale for new terminologies in NAFLD
Michal	Gillon-Keren	Israel	The role of nutrition management in people using automated insulin delivery systems
Francesco	Giorgino	Italy	Incretin-based therapies for the treatment of obesity-related diseases
Amit	Gupta	India	Intermittent use of CGM in type 2 diabetes
Michael	Haller	USA	· Inhaled insulin in pediatrics (INHALE-1 – Peds Study)
			· Stages and monitoring in early type 1 diabetes
Matthias	Hebrok	Germany	Optimizing stem cell derived beta cell function for transplantation
Tim	Heise	Germany	Oral and glucose-sensitive insulins: Will we ever have them?
Simon	Heller	UK	Is it possible to reserve awareness of hypoglycemia with AID technology?
Norbert	Hermanns	Germany	How to achieve a precision medicine approach using CGM and ecological momentary assessment
Julie	Heverly	USA	Time in tight glycemic range – A crucial goal or an unnecessary burden: PwD perspective

Irl	Hirsch	USA	<ul style="list-style-type: none"> What's new in pulmonary inhaled insulin? What are the appropriate glucose targets in the ICU? CGM-based intensification and de-intensification of therapy in type 2 diabetes
Korey	Hood	USA	Scoping out gaps in automation in the diabetes tech space
Roman	Hovorka	UK	How do I see the future of AID?
Sufyan	Hussain	UK	<ul style="list-style-type: none"> How to use hybrid-closed-loop systems in complex outpatient clinical situations Fully closed-loop – Can people just do it? Insights from approaches using current commercial and open-source (DIY) HCL systems
Daria	Igudesman	USA	The role of nutrition in optimizing outcomes of GLP1/GIP
Peter	Jacobs	USA	AI-enabled meal detection and dosing in automated insulin delivery systems
Laura	Jacobsen	USA	DEBATE: Adaptive trials in the Post-Teplizumab era: To placebo or not to placebo? No, we should use only active (approved) control
Anna	Kahkoska	USA	<ul style="list-style-type: none"> Use of technology to re-align treatment in individuals with type 2 diabetes in various living situations Use of CGM to improve the care of older insulin dependent individuals with cognitive / functional impairment
Partha	Kar	UK	The reality of the use of technology – Introduction
Karen	Kennedy	UK	<i>With Eleanor Scott:</i> Bringing science into lives: The Implementers
David	Kerr	USA	Time in tight glycemic range – A crucial goal or an unnecessary burden: Health inequalities perspective
Jothydev	Kesavadev	India	From insulin pumps to aid in India: Status of adoptability among people, physicians, and politicians
Tomasz	Klupa	Poland	Use of AID systems in order to improve the care of older individuals with type 1 diabetes & cognitive / functional impairment
Noriko	Kodani	Japan	PwD voices in designing new technology options for treating diabetes: The Diabetes Designer
Antje	Körner	Germany	A holistic approach to understanding childhood obesity
Primož	Kotnik	Slovenia	Therapy for monogenic obesity
Boris	Kovatchev	USA	<ul style="list-style-type: none"> How digital twins can enhance clinical trials Machine learning – The key to fully automated closed-loop
Bernhard	Kulzer	Germany	AID, CSII & CGM: Real-world insights
Lori	Laffel	USA	<ul style="list-style-type: none"> Is there ongoing need for telehealth? Use of GLP1 analogs in youth with type 1 diabetes for weight management in youth SGLT2i use in young people following approval by FDA and EMA in type 2 diabetes
Goos	Laverman	The Netherlands	Taking optimal advantage of diabetes technology: Potential role of a technical physician in your team
David	Maahs	USA	Remote patient monitoring, logistics and challenges for reimbursement

Julia	Mader	Austria	<ul style="list-style-type: none"> Navigating the skies: Managing diabetes during air travel Trends of diabetes technology use in different European countries
			Editorial perspectives and ISPAD type 2 diabetes chapter update
Farid	Mahmud	Canada	Editorial perspectives and ISPAD type 2 diabetes chapter update
Marco	Marigliano	Italy	Cam APS Fx in very young children in Italy (2-year follow up)
Chantal	Mathieu	Belgium	<ul style="list-style-type: none"> EDENTIFI: Towards general population screening in Europe Precision medicine in stage 2 type 1 diabetes
			<ul style="list-style-type: none"> EDENTIFI: Towards general population screening in Europe Precision medicine in stage 2 type 1 diabetes
Jamie	Matu	UK	Advances in pharmacological interventions for pediatric and adolescent obesity – Current status and future prospects
Barbara	McGowan	UK	New horizons for treating obesity
Viswanathan	Mohan	India	Do different types of prediabetes require different types of prevention approaches?
Othmar	Moser	Germany	<ul style="list-style-type: none"> The use of AID and exercise in type 1 diabetes: A position statement of the EASD and ISPAD Fully closed-loop: From announced to unannounced exercise
			<ul style="list-style-type: none"> AI analytics and CGM data science Using exercise data in combination of AI to help prevent nocturnal hypoglycemia
Marie	Mouler	Israel	Diabetes technology in competitive sports: The queen's gambit
Medha	Munshi	USA	Use of technology to re-align treatment in individuals with type 1 diabetes in various living situations
Helen	Murphy	UK	The role of CamAPS FX in type 1 diabetes pregnancy
Joshua	Neumiller	USA	Triggers that indicate need for re-alignment in older adults with diabetes
Revital	Nimri	Israel	Decision support systems for healthcare providers and people with diabetes
Kirsten	Nørgaard	Denmark	<ul style="list-style-type: none"> Can decision support for evaluating automated insulin delivery (AID) uploads assist clinicians? Status on Stenpool – An uploading program with access to all devices
			<ul style="list-style-type: none"> Can decision support for evaluating automated insulin delivery (AID) uploads assist clinicians? Status on Stenpool – An uploading program with access to all devices
Maria Cristina	Nostro	USA	Optimizing differentiation and engraftment of stem cell-derived islets for type 1 diabetes treatment
Tal	Oron	Israel	With Moshe Phillip: Update on ADIR (Antibody Detection Israeli Research) project
Naushira	Pandya	USA	Treatment of type 1 diabetes in long term care facilities
Rakesh	Parikh	India	Artificial intelligence (AI) in diabetes clinic: Expanding horizons
Ewan R	Pearson	UK	Heterogeneity of obesity and type 2 diabetes diabetes
John	Pemberton	UK	A paradigm shift: Using CGM to dose physical activity between meals to optimize time in range
Jeremy	Pettus	USA	View, Counterview: Time in tight range should be the primary treatment goals and outcome measure in diabetes – Counterview
Moshe	Phillip	Israel	With Tal Oron: Update on ADIR (Antibody Detection Israeli Research) project
Elizabeth	Pyatak	USA	Individual networks between glucose, mood, and daily functioning

Neesha	Ramchandani	USA	Giving your best shot: Focusing on safety, efficacy & comfort
Eric	Renard	France	<ul style="list-style-type: none"> Fully closed-loop – Insulin only approaches Diabetes technology in different age groups
			Different ways to detect unawareness
Michael	Rickels	USA	Physical activity, technology and type 2 diabetes: Opportunities and challenges
Julio	Rosenstock	USA	<ul style="list-style-type: none"> Should GLP-1 RAs be stopped prior to elective surgery? Triple agonist in type 2 diabetes
			Lessons from the SELECT trial: Rethinking the clinical applications for the GLP-1RA semaglutide
Victoria	Salem	UK	Biomaterials to aid beta cell replacement – Current and future perspectives
Andrea	Scaramuzza	Italy	Which are the best therapeutic strategies when exercising? Comparison among different AID systems
Desmond	Schatz	USA	Update on efforts to interdict type 1 diabetes
Eleanor	Scott	UK	With Karen Kennedy: Bringing science into lives: The Implementers
Jane Jeffrie	Seley	USA	Innovative models that support inpatient diabetes care & education
Jazz	Sethi	India	Together with Kamil Armacky: The benefits / disadvantages of social media in context of technology: The Diabfluencers
Viral	Shah	USA	Use of CGM in pre-type 2 diabetes
Anath	Shalev	USA	Novel type 1 diabetes therapies targeting endogenous islet cells
Shlomit	Shalitin	Israel	Prevalence of obesity in type 1 diabetes
Devorah	Shapiro	Israel	Growing bigger and independent – A structured educational program for patients aged 9 -12 who were diagnosed at a very young age
Jennifer	Sherr	USA	<ul style="list-style-type: none"> Evidence and ideas from automated insulin delivery on the user experience of automation DEBATE: Is there a real unmet need for continuous ketone monitoring – PRO
Smadar	Shilo	Israel	Data-Driven approaches in endocrinology: From CGM to omics data
Galit	Shiovitch-Mantzuri	Israel	Follow-up of families with early detection of type 1 diabetes; The nurse perspective
Carmel	Smart	Australia	<ul style="list-style-type: none"> Changing behaviors to manage weight in children and adolescents with type 1 diabetes Is carb counting enough? Optimizing mealtime insulin dosing
Darja	Šmigoc Schweiger	Slovenia	Sex differences in cardiovascular risk factor in youth with type 1 diabetes
Harald	Sourij	Austria	Exercise and long-acting insulins
Courtney	South	Canada	The impact of technology use on diabetes-related nutrition behaviors
Andrew F	Stewart	USA	Human beta cell regenerative drug therapy: A journey from impossible to possible
Jannet	Svensson	Denmark	Diabetes technology and sleep
Molly	Tanenbaum	USA	Time in tight glycemic range: A crucial goal or an unnecessary burden – Qualitative data perspective

Maria	Vasiloglou	Switzerland	Effectiveness of app-based interventions on diabetes and nutrition
Josep	Vehi	Spain	Applications of generative AI to diabetes
Deborah	Wake	UK	AI takes diabetes management beyond AID
Emma	Wilmot	UK	What do people with diabetes expect from diabetes technology?
Yariv	Yogev	Israel	How do you know that your pregnant woman with diabetes is well controlled?